Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Open accessAbstract
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the recent development of anti-amyloid-β (Aβ) immunotherapies. Several assays for measuring phosphorylated tau (p-tau) in plasma exhibit high diagnostic accuracy in distinguishing AD from all other neurodegenerative diseases in patients with cognitive impairment. Prognostic models based on plasma p-tau levels can also predict future development of AD dementia in patients with mild cognitive complaints. The use of such high-performing plasma p-tau assays in the clinical practice of specialist memory clinics would reduce the need for more costly investigations involving cerebrospinal fluid samples or positron emission tomography. Indeed, blood-based biomarkers already facilitate identification of individuals with pre-symptomatic AD in the context of clinical trials. Longitudinal measurements of such biomarkers will also improve the detection of relevant disease-modifying effects of new drugs or lifestyle interventions.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Blood-based biomarkers for AD could support the diagnosis of AD in clinical practice and improve the development of clinical trials for the earliest stages of AD.
“Indeed, blood-based biomarkers for AD could pave the way in supporting the diagnosis of AD in clinical practice and in improving the development of clinical trials for the earliest stages of AD [53,54,55].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [54]
Sufficiently high PPVs or NPVs of plasma biomarkers for AD pathology could circumvent the need for the majority of PET or CSF testing, with confirmatory testing used in remaining situations with lower predictive values.
“Sufficiently high positive predictive values (PPVs) or negative predictive values (NPVs) of plasma biomarkers for AD pathology could circumvent the need for the majority of PET or CSF testing, with confirmatory testing used in remaining situations with lower predictive values3,16.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [3]
Blood-based markers capable of detecting AD pathology have been developed.
“In the last several years, blood-based markers (BBMs) capable of detecting AD pathology have been developed16–18.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [17]
The two-cutoffs approach is currently employed for the FDA-approved CSF Lumipulse test and has been suggested for AD blood-based biomarkers, especially when very high accuracy is needed.
“Notably, the two-cutoffs approach is currently employed for the FDA-approved CSF Lumipulse test42,43 and has been suggested for AD BBMs17,55, especially when very high accuracy is needed.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [17]
Patients received diagnoses based on established clinical criteria only, without testing for ATN biomarkers in AD.
“Second, patients received diagnoses based on established clinical criteria only,37,38 without testing for ATN biomarkers in AD such as the deposition of amyloid-β and tau proteins established via Positron Emission Tomography, CSF, or plasma in AD.94, 95, 96, 97”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · see citing works
Using Effect Size—or Why the P Value Is Not Enough
Sullivan, G. M., & Feinn, R. (2012) · Journal of Graduate Medical Education · doi:10.4300/jgme-d-12-00156.1 · Cited by 5,553 · see citing works
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1× · see citing works
“tine practice in clinical assessments and research studies, probably combined with (1) high-performing assays of plasma Aβ42/Aβ40 ratio for preclinical AD (Fig.”
BackgroundNeurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · see citing works
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · see citing works
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681 · see citing works
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · see citing works
Self-citationTwo Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367 · see citing works
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316 · see citing works
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247 · see citing works
Self-citationSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164 · see citing works
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159 · see citing works
Self-citationAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070 · see citing works
Self-citationBlood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045 · see citing works
Self-citationBiomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000 · see citing works
Self-citationMissed and Delayed Diagnosis of Dementia in Primary Care: Prevalence and Contributing Factors
Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P., & Singh, H. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181a6bebc · Cited by 969 · see citing works
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · see citing works
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · see citing works
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · see citing works
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808 · see citing works
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761 · see citing works
Self-citationFour distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741 · see citing works
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719 · see citing works
Self-citationBuchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664 · see citing works
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638 · see citing works
Self-citationPlasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626 · see citing works
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621 · see citing works
Self-citationHansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607 · see citing works
Self-citationPlasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598 · see citing works
Self-citationTau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works
Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585 · see citing works
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545 · see citing works
Self-citationPalmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524 · see citing works
Self-citationHead-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522 · see citing works
Self-citationOssenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02049-x · Cited by 496 · see citing works
Self-citationHead-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3180 · Cited by 494 · see citing works
Self-citationZetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · see citing works
Self-citationGisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.036 · Cited by 481 · see citing works
Self-citationOssenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472 · see citing works
Self-citationPerformance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465 · see citing works
Self-citationJanelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456 · see citing works
Self-citationDonohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452 · see citing works
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450 · see citing works
Self-citationCerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450 · see citing works
Self-citationFleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448 · see citing works
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437 · see citing works
Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436 · see citing works
Self-citationPalmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435 · see citing works
Self-citationAmyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Vickle, G. D. V., Kalback, W. M., Patton, R., Luehrs, D. C., Daugs, I. D., Kuo, Y., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.10.004 · Cited by 411 · see citing works
Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401 · see citing works
Self-citationPalmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400 · see citing works
Self-citationJanelidze, S., Berron, D., Smith, R. A., Strandberg, O. T., Proctor, N. K., Dage, J. L., Stomrud, E., Palmqvist, S., Mattsson, N., & Hansson, O. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4201 · Cited by 390 · see citing works
Self-citationBrickman, A. M., Manly, J. J., Honig, L. S., Sanchez, D., Reyes‐Dumeyer, D., Lantigua, R. A., Lao, P. J., Stern, Y., Vonsattel, J. P., Teich, A. F., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12301 · Cited by 387 · see citing works
Self-citationDetailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375 · see citing works
Self-citationLongitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., Mengel, D., Walsh, D. M., Stomrud, E., Dage, J. L., et al. (2020) · Brain · doi:10.1093/brain/awaa286 · Cited by 368 · see citing works
Self-citationMattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359 · see citing works
Self-citationA trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359 · see citing works
Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353 · see citing works
Self-citationMilà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353 · see citing works
Self-citationKarikari, T. K., Benedet, A. L., Ashton, N. J., Lantero‐Rodriguez, J., Snellman, A., Suárez‐Calvet, M., Saha‐Chaudhuri, P., Lussier, F. Z., Kvartsberg, H., Moscoso, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00923-z · Cited by 348 · see citing works
Self-citationDeveloping the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H. J., Cummings, J. L., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 331 · see citing works
Self-citationBlood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu‐Gaya, L., Lantero‐Rodriguez, J., Pascoal, T. A., Suárez‐Calvet, M., Rosa‐Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 327 · see citing works
Self-citationInitial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
Öst, M., Nylén, K., Csajbok, L., Öhrfelt, A. O., Tullberg, M., Wikkelsö, C., Nellgård, P., Rosengren, L., Blennow, K., & Nellgård, B. (2006) · Neurology · doi:10.1212/01.wnl.0000242732.06714.0f · Cited by 321 · see citing works
Self-citationOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311 · see citing works
Self-citationCicognola, C., Janelidze, S., Hertze, J., Zetterberg, H., Blennow, K., Mattsson, N., & Hansson, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00804-9 · Cited by 309 · see citing works
Self-citationMattsson-Carlgren, N., Salvadó, G., Ashton, N. J., Tideman, P., Stomrud, E., Zetterberg, H., Ossenkoppele, R., Betthauser, T. J., Cody, K. A., Jonaitis, E. M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5272 · Cited by 309 · see citing works
Self-citationPrevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5216 · Cited by 290 · see citing works
Self-citationBlood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J., & Hansson, O. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 269 · see citing works
Self-citationTherriault, J., Vermeiren, M. R., Servaes, S., Tissot, C., Ashton, N. J., Benedet, A. L., Karikari, T. K., Lantero‐Rodriguez, J., Brum, W. S., Lussier, F. Z., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4485 · Cited by 268 · see citing works
Self-citationSoluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Mattsson‐Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114022 · Cited by 261 · see citing works
Self-citationPontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3392 · Cited by 261 · see citing works
Self-citationVerberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258 · see citing works
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities
Syrjanen, J. A., Campbell, M. R., Algeciras‐Schimnich, A., Vemuri, P., Graff‐Radford, J., Machulda, M. M., Bu, G., Knopman, D. S., Jack, C. R., Petersen, R. C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12466 · Cited by 248 · see citing works
Brum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00471-5 · Cited by 248 · see citing works
Self-citationMielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.2293 · Cited by 244 · see citing works
Self-citationVerberk, I. M. W., Misdorp, E. O., Koelewijn, J., Ball, A. J., Blennow, K., Dage, J. L., Fandos, N., Hansson, O., Hirtz, C., Janelidze, S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12510 · Cited by 241 · see citing works
Self-citationRiemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238 · see citing works
Ashton, N. J., Puig‐Pijoan, A., Milà‐Alomà, M., Fernández‐Lebrero, A., García‐Escobar, G., González‐Ortiz, F., Kac, P. R., Brum, W. S., Benedet, A. L., Lantero‐Rodriguez, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12841 · Cited by 230 · see citing works
Self-citationTime course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Rodriguez, J. L., Snellman, A., Suárez-Calvet, M., Zetterberg, H., Blennow, K., Schöll, M., et al. (2021) · Brain · doi:10.1093/brain/awaa399 · Cited by 229 · see citing works
Self-citationPichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12787 · Cited by 226 · see citing works
Self-citationWest, T., Kirmess, K. M., Meyer, M. R., Holubasch, M. S., Knapik, S. S., Hu, Y., Contois, J. H., Jackson, E. N., Harpstrite, S. E., Bateman, R. J., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00451-6 · Cited by 222 · see citing works
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
Benatar, M. G., Zhang, L., Wang, L. H.-C., Granit, V., Statland, J., Barohn, R. J., Swenson, A., Ravits, J., Jackson, C. E., Burns, T. M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009559 · Cited by 205 · see citing works
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205 · see citing works
Self-citationVerberk, I. M. W., Laarhuis, M. B., van den Bosch, K. A., Ebenau, J. L., van Leeuwenstijn, M. S. S. A., Prins, N. D., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30061-1 · Cited by 203 · see citing works
Simrén, J., Andréasson, U., Gobom, J., Suárez‐Calvet, M., Borroni, B., Gillberg, C., Nyberg, L. H., Ghidoni, R., Fernell, E., Johnson, M., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac174 · Cited by 196 · see citing works
Self-citationValidation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
Li, Y., Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Weiner, M. W., Shaw, L. M. J., Masters, C. L., Fowler, C. J., Trojanowski, J. Q., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013211 · Cited by 194 · see citing works
Self-citationJanelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12395 · Cited by 188 · see citing works
Self-citationBayoumy, S., Verberk, I. M. W., den Dulk, B., Hussainali, Z., Zwan, M. D., van der Flier, W. M., Ashton, N. J., Zetterberg, H., Blennow, K., Vanbrabant, J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00939-9 · Cited by 188 · see citing works
Self-citationCullen, N. C., Leuzy, A., Palmqvist, S., Janelidze, S., Stomrud, E., Pesini, P., Sarasa, L., Allué, J. A., Proctor, N. K., Zetterberg, H., et al. (2020) · Nature Aging · doi:10.1038/s43587-020-00003-5 · Cited by 187 · see citing works
Self-citationPlasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182 · see citing works
Self-citationCSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180 · see citing works
Janelidze, S., Barthélemy, N. R., He, Y., Bateman, R. J., & Hansson, O. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0199 · Cited by 176 · see citing works
Self-citationAn accurate fully automated panel of plasma biomarkers for Alzheimer's disease
Palmqvist, S., Stomrud, E., Cullen, N. C., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12751 · Cited by 161 · see citing works
Self-citationNFL is a marker of treatment response in children with SMA treated with nusinersen
Olsson, B., Alberg, L., Cullen, N. C., Michael, E., Wahlgren, L., Kroksmark, A., Rostasy, K. M., Blennow, K., Zetterberg, H., & Tulinius, M. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09389-8 · Cited by 159 · see citing works
Self-citationTau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.04.035 · Cited by 154 · see citing works
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4654 · Cited by 149 · see citing works
Self-citationGobom, J., Parnetti, L., Rosa-Neto, P., Vyhnalek, M., Gauthier, S., Cataldi, S., Lerch, O., Laczo, J., Cechova, K., Clarin, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0651 · Cited by 146 · see citing works
Self-citation(2015) · Europe PMC (PubMed Central) · Cited by 143 · see citing works
Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143 · see citing works
Self-citationTemporal order of clinical and biomarker changes in familial frontotemporal dementia
Staffaroni, A. M., Quintana, M., Wendelberger, B., Heuer, H. W., Russell, L. L., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Petrucelli, L., Gendron, T. F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01942-9 · Cited by 140 · see citing works
Self-citationBlood neurofilament light levels segregate treatment effects in multiple sclerosis
Delcoigne, B., Manouchehrinia, A., Barro, C., Benkert, P., Michalak, Z., Kappos, L., Leppert, D., Tsai, J. A., Plavina, T., Kieseier, B. C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009097 · Cited by 140 · see citing works
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Benedet, A. L., Brum, W. S., Hansson, O., Initiative, A. D. N., Karikari, T. K., Zimmer, E. R., Zetterberg, H., Blennow, K., & Ashton, N. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00942-0 · Cited by 139 · see citing works
Self-citationHansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136 · see citing works
Self-citationCSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation
Kuhlmann, J., Andréasson, U., Pannee, J., Bjerke, M., Portelius, E., Leinenbach, A., Bittner, T., Korecka, M., Jenkins, R. G., Vanderstichele, H., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.014 · Cited by 134 · see citing works
Self-citationMattsson, N., Grinberg, L. T., Boxer, A. L., Ossenkoppele, R., Jonsson, M., Seeley, W., Ehrenberg, A. J., Spina, S., Janelidze, S., Rojas-Martinex, J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200040 · Cited by 134 · see citing works
Self-citationCerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Sämgård, K., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., & Londos, E. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2353 · Cited by 133 · see citing works
Self-citationDetermining clinically meaningful decline in preclinical Alzheimer disease
Insel, P. S., Weiner, M., Mackin, R. S., Mormino, E., Lim, Y. Y., Stomrud, E., Palmqvist, S., Masters, C. L., Maruff, P. T., Hansson, O., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007831 · Cited by 128 · see citing works
Self-citationLeuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology · doi:10.1212/wnl.0000000000012727 · Cited by 128 · see citing works
Self-citationHu, Y., Kirmess, K. M., Meyer, M. R., Rabinovici, G. D., Gatsonis, C., Siegel, B. A., Whitmer, R. A., Apgar, C., Hanna, L., Kanekiyo, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8392 · Cited by 120 · see citing works
The implications of different approaches to define AT(N) in Alzheimer disease
Mattsson-Carlgren, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R., & Hansson, O. (2020) · Neurology · doi:10.1212/wnl.0000000000009485 · Cited by 114 · see citing works
Self-citationRodrigues, F. B., Byrne, L. M., Tortelli, R., Johnson, E. B., Wijeratne, P. A., Arridge, M., Vita, E. D., Ghazaleh, N., Houghton, R., Furby, H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc2888 · Cited by 114 · see citing works
Self-citationCorrelation of In Vivo [<sup>18</sup>F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology
Smith, R., Wibom, M., Pawlik, D., Englund, E., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3692 · Cited by 111 · see citing works
Self-citationAnti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy
Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100 · see citing works
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99 · see citing works
Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening
Rabe, C., Bittner, T., Jethwa, A., Suridjan, I., Manuilova, E., Friesenhahn, M. J., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12801 · Cited by 87 · see citing works
Self-citationAutoimmune Encephalitis Resembling Dementia Syndromes
Bastiaansen, A. E. M., van Steenhoven, R. W., de Bruijn, M. A. A. M., Crijnen, Y. S., van Sonderen, A., van Coevorden‐Hameete, M. H., Nühn, M. M., Verbeek, M. M., Schreurs, M. W. J., Smitt, P. A. E. S., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001039 · Cited by 85 · see citing works
van der Kall, L. M., Truong, T. H., Burnham, S. C., Doré, V., Mulligan, R. S., Bozinovski, S., Lamb, F., Bourgeat, P., Fripp, J., Schultz, S. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011222 · Cited by 84 · see citing works
Cullen, N. C., Janelidze, S., Mattsson, N., Palmqvist, S., Bittner, T., Suridjan, I., Jethwa, A., Kollmorgen, G., Brum, W. S., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12706 · Cited by 84 · see citing works
Self-citationFirst amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
Boulo, S., Kuhlmann, J., Andréasson, U., Brix, B., Venkataraman, I., Herbst, V., Rutz, S., Manuilova, E., Vandijck, M. L. J., Dekeyser, F., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12145 · Cited by 65 · see citing works
Self-citationTowards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62 · see citing works
Self-citationTau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients
Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12875 · Cited by 60 · see citing works
Self-citationComparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Mielke, M. M., Aakre, J. A., Algeciras‐Schimnich, A., Proctor, N. K., Machulda, M. M., Eichenlaub, U., Knopman, D. S., Vemuri, P., Graff‐Radford, J., Jack, C. R., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12415 · Cited by 55 · see citing works
Self-citationNing, L., & Wang, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274565 · Cited by 55 · see citing works
Hanes, J., Kováč, A., Kvartsberg, H., Kontseková, E., Fialová, Ľ., Katina, S., Kováčech, B., Stevens, E., Hort, J., Vyhnálek, M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010814 · Cited by 54 · see citing works
Self-citationGroot, C., Smith, R. A., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson, N., Janelidze, S., et al. (2022) · Brain · doi:10.1093/brain/awac329 · Cited by 50 · see citing works
Self-citationComparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI
Windon, C., Iaccarino, L., Mundada, N. S., Allen, I. E., Boxer, A. L., Byrd, D., Mindt, M. R., Rabinovici, G. D., & ADNI (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12315 · Cited by 49 · see citing works
The global Alzheimer's Association round robin study on plasma amyloid β methods
Pannee, J., Shaw, L. M. J., Korecka, M., Waligórska, T., Teunissen, C. E., Stoops, E., Vanderstichele, H., Mauroo, K., Verberk, I. M. W., Keshavan, A., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12242 · Cited by 48 · see citing works
Self-citationSalvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12907 · Cited by 46 · see citing works
Self-citationLeuzy, A., Mattsson, N., Cullen, N. C., Stomrud, E., Palmqvist, S., Joie, R. L., Iaccarino, L., Zetterberg, H., Rabinovici, G. D., Blennow, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12897 · Cited by 43 · see citing works
Self-citationKaeser, S. A., Häsler, L. M., Lambert, M., Bergmann, C., Bottelbergs, A., Theunis, C., Mercken, M. H., & Jucker, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02400-5 · Cited by 41 · see citing works
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
Portelius, E., Mattsson, N., Pannee, J., Zetterberg, H., Gisslén, M., Vanderstichele, H., Gkanatsiou, E., Crespi, G. A. N., Parker, M. W., Miles, L. A., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0152-5 · Cited by 39 · see citing works
Self-citationAndréasson, U., Kuhlmann, J., Pannee, J., Umek, R. M., Stoops, E., Vanderstichele, H., Matzen, A., Vandijck, M. L. J., Dauwe, M., Leinenbach, A., et al. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0147 · Cited by 38 · see citing works
Self-citationUsing Alzheimer's disease blood tests to accelerate clinical trial enrollment
Schindler, S. E., Li, Y., Li, M., Despotis, A., Park, E., Vittert, L., Hamilton, B. H., Womack, K. B., Saef, B., Holtzman, D. M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12754 · Cited by 38 · see citing works
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
Hansson, O., Cullen, N. C., Zetterberg, H., Initiative, T. A. D. N., Blennow, K., & Mattsson, N. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51253 · Cited by 35 · see citing works
Self-citationMank, A., van Maurik, I. S., Bakker, E. D., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12189 · Cited by 31 · see citing works
Winston, C. N., Langford, O., Levin, N., Raman, R., Yarasheski, K. E., West, T., Abdel‐Latif, S., Donohue, M., Nakamura, A., Toba, K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221118 · Cited by 16 · see citing works
Comparison of plasma and CSF biomarkers across ethnoracial groups in ADNI
Windon, C., Iaccarino, L., Allen, I. E., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.056590 · Cited by 15 · see citing works
Cullen, N. C., Janelidze, S., Stomrud, E., Bateman, R. J., Palmqvist, S., Hansson, O., & Mattsson, N. (2023) · Brain Communications · doi:10.1093/braincomms/fcad015 · Cited by 14 · see citing works
Self-citationWhat's Happening in Neurology® Genetics
(2021) · Neurology · doi:10.1212/wnl.0000000000011707 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884 · see citing works
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448 · see citing works
“In a second approach, we created three groups of participants (that is, positive, negative and intermediate) using two different thresholds, as recently described 17 .”
MethodInfluentialSelf-citationBlood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., et al. (2024) · JAMA · doi:10.1001/jama.2024.13855 · Cited by 416 · see citing works
Self-citationAlzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170 · see citing works
Mattsson-Carlgren, N., Collij, L. E., Stomrud, E., Pichet Binette, A., Ossenkoppele, R., Smith, R., Karlsson, L., Lantero-Rodriguez, J., Snellman, A., Strandberg, O., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4596 · Cited by 148 · see citing works
Self-citationArtificial intelligence for biomarker discovery in Alzheimer's disease and dementia
Winchester, L. M., Harshfield, E. L., Shi, L., Badhwar, A., Khleifat, A. A., Clarke, N., Dehsarvi, A., Lengyel, I., Lourida, I., Madan, C. R., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13390 · Cited by 130 · see citing works
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00731-y · Cited by 112 · see citing works
“Sufficiently high positive predictive values (PPVs) or negative predictive values (NPVs) of plasma biomarkers for AD pathology could circumvent the need for the majority of PET or CSF testing, with confirmatory testing used in remaining situations with lower predictive values 3,16 .”
Self-citationTreatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94 · see citing works
Hazelton, J. L., Della Bella, G., Barttfeld, P., Dottori, M., Gonzalez-Gomez, R., Migeot, J., Moguilner, S., Legaz, A., Hernandez, H., Prado, P., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105614 · Cited by 14 · see citing works
Data‐driven evaluation of suitable immunogens for improved antibody selection
Waury, K., Kvartsberg, H., Zetterberg, H., Blennow, K., Teunissen, C. E., & Abeln, S. (2025) · Protein Science · doi:10.1002/pro.70100 · Cited by 1 · see citing works
“Results indicated that longer immunogens often resulted in more successful but less specific antibodies.”
Self-citation
- Authors
- Hansson, O., Blennow, K., Zetterberg, H., & Dage, J.
- Affiliations
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- University of Wisconsin–Madison (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Hansson, Oskar
- Venue
- Nature Aging
- Published
- 2023-05-18
- Volume
- 3
- Issue
- 5
- Pages
- 506-519
- ISSN
- 2662-8465 (ISSN-L)
- PMC
- PMC10979350
- OpenAlex
- W4377029875
- Cited by
- 522
- References
- 141
- Citations by year
- 2026: 178 · 2025: 184 · 2024: 140 · 2023: 20
- FWCI
- 23.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Aging (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Vetenskapsrådet (2022-00775)
- Knut och Alice Wallenbergs Stiftelse (2017-0383)
- Hjärnfonden (FO2021-0293)
- Cure Alzheimer’s Fund (NA)
- Swedish federal government under the ALF agreement
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, blood biomarkers, amyloid-beta, anti-amyloid immunotherapy, preclinical Alzheimer's disease, mild cognitive impairment, dementia prediction, diagnostic accuracy, prognostic model, memory clinics
- MeSH terms
- Alzheimer Disease, Humans, Tomography, X-Ray Computed, Biomarkers, Amyloid beta-Peptides, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
